Clinical Scorecard: Reporting Graft Outcomes to Support Organ Donation After Out-of-Hospital Cardiac Arrest Caused by Aneurysmal Subarachnoid Haemorrhage

At a Glance

Key Highlights

• The cohort reported favourable outcomes in 8 patients (4.9%); seven had an mRS score of 2–3 and one had an mRS score of 0–1.
• Aneurysm-treatment comparisons are vulnerable to confounding by indication and immortal-time bias; no untreated patient with a favourable outcome was available as a comparator.
• Brain death occurred early in the cohort, at a median of 1 day; the authors argue that time-resolved clinical and treatment data are needed to clarify patient trajectories.
• Among brain-dead patients, 45.4% proceeded to donation, but the cohort did not report organs retrieved or transplanted, graft function, or recipient outcomes.
• The article discusses controlled donation after circulatory death as a possible donation pathway when life-sustaining therapy is withdrawn independently of donation considerations, subject to eligibility and local protocols.

Guideline-Based Recommendations

Diagnosis

• The article notes that GCS after cardiac arrest may reflect absent cerebral perfusion rather than intrinsic brain injury; admission GCS and modified Fisher grade did not distinguish outcome groups in the reported cohort.
• The authors state that neurological prognostication should be deferred until the effects of cardiac arrest, sedation, and early brain injury can be assessed more reliably.

Management

• The article cites current aSAH guidelines recommending that the ruptured aneurysm be secured as early as possible, preferably within 24 hours, to lower rebleeding risk.
• The authors support ICU admission for every patient and avoidance of very early withdrawal of life-sustaining therapy.
• The article describes MRI at approximately 48 hours as a possible aid to assessing hypoxic–ischaemic injury; diffusion abnormalities may be less likely to be overlooked than during the first 24 hours.
• Donation after brain death or controlled circulatory death may be considered subject to eligibility and local protocols; withdrawal decisions should be independent of organ-donation considerations.

Monitoring & Follow-up

• The authors recommend reporting timing of return of spontaneous circulation, aneurysm securing, rebleeding, neurological prognostication, brain death, and withdrawal of life-sustaining therapy.
• Prospective data collection should include donation pathway, organs retrieved and transplanted, graft and recipient outcomes, and reasons for non-donation.

Risks

• Rebleeding is most prevalent during the first 72 hours and among poor-grade patients, as cited in the article.
• Aneurysm-treatment comparisons may be biased by early survival, clinical selection, and immortal time.
• Whole-body ischaemia–reperfusion injury after cardiac arrest is a concern for graft quality; the cohort did not report graft or recipient outcomes.
• The article notes that the reported c-index may be optimistic because there were eight candidate predictors for seven favourable outcomes and no internal validation.

Patient & Prescribing Data

The cited multicentre cohort included 164 patients with OHCA-aSAH; 8 (4.9%) had favourable outcomes, and 124 (75.6%) received no aneurysm treatment.

All eight patients with favourable outcomes underwent coiling, compared with 18.6% of those with poor outcomes. The article cautions that this association does not establish a treatment effect because of clinical selection, early-survival dependence, and the absence of an untreated favourable-outcome comparator.

Clinical Best Practices

• Interpret treatment-outcome associations in OHCA-aSAH cautiously when treatment timing and early survival are not reported.
• Record time-resolved clinical events to help distinguish treatment effects from selection and survivorship.
• Avoid interpreting early brain-death timing as support for delaying aneurysm treatment; the article cites guidance to secure the aneurysm preferably within 24 hours.
• Report donation and transplantation outcomes, including organs retrieved and transplanted, graft function, recipient outcomes, and reasons for non-donation.
• Keep decisions to withdraw life-sustaining therapy independent of organ-donation considerations.

Related Resources & Content

• Legros et al. multicentre cohort study, as cited in the article
• References 2–15 cited in the article; bibliographic details and URLs were not provided